SOURCE: BioMedReports

BioMedReports

August 19, 2010 07:00 ET

False Starts by Others Don't Discourage Intellect Neurosciences' Search for Alzheimer's Treatment

LOS ANGELES, CA--(Marketwire - August 19, 2010) -  In an exclusive commentary, Dr. Daniel Chain, Chief Executive Officer of Intellect Neurosciences (OTCBB: ILNS), tells BioMedReports that in contrast to many biopharmaceutical companies focused on Alzheimer's disease (AD), Intellect Neurosciences is developing multiple therapeutic approaches and technologies aimed at slowing down, arresting or preventing this devastating disease.

Unfortunately, there have been numerous false starts by other companies attempting to develop novel therapies to prevent the buildup of amyloid beta in the brain. The latest culprit was Eli Lilly who until recently was developing Semagacesta.

This week, researchers and investors were dismayed by what the New York Times best described as the setback for Lilly: "The study seemed to raise questions about a leading hypothesis of the cause of Alzheimer's and how to treat it."

According to Chain, however, an understanding of the background and the drug's mechanism of action affecting the function of a physiologically important protein may be helpful to avoid casting the baby out with the bathwater.

Dr. Chain remains firmly convinced, based on years of research and evidence from genetic, epidiemological, transgenic models and clinical data that the accumulation of soluble amyloid beta in the brain results in a neurodegenerative process that ultimately leads to AD. His opinion is shared by the vast majority of scientists and clinicians involved in Alzheimer's research. "I am unaware of any clinical or other data that casts doubt on my strong belief," says Chain.

The Company's impressive pipeline includes preclinical and clinical stage products and its licenses to some of the world's largest pharmaceutical companies cover late-clinical stage products under development. Each of the Company's programs utilizes a separate and distinct therapeutic approach.

The full commentary and report is available to investors at BioMedReports.Com:

http://biomedreports.com/articles/most-popular/51039-exclusive-numerous-false-starts-by-others-dont-discourage-this-companys-search-for-alzheimers-treatment.html

About BioMedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies.

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556